Payment overview · 2025
General Payments
$1,627.41
42 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Stephen Fredericks, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · RENO, NV · NPI 1336156546
Verified facts
What the public records show
CMS Open Payments records show Robert Stephen Fredericks, MD received $1,627.41 in general payments during 2025 across 42 reported records.
Ascendis Pharma Endocrinology Inc accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Omnitrope.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Sandoz Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OMNITROPE as an associated drug or biological on 65 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Omnitrope by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $366.49 | 22.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.11 | 13.6% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $174.39 | 10.7% | 7 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $162.91 | 10.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $140.75 | 8.7% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $130.25 | 8.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $99.44 | 6.1% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $73.37 | 4.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.66 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.08 | 3.0% | 2 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $34.70 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.48 | 2.0% | 1 | 2025 |
| Lexicon Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.00 | 1.8% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.95 | 1.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.96 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.87 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,627.41 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $366.49 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $174.39 | 7 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $162.91 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $140.75 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $130.25 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $99.44 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.58 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $73.37 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $73.37 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $73.37 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $49.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| OMNITROPE Normalized: omnitrope |
Biological | Sandoz Inc. | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| Sogroya Normalized: sogroya |
Biological | Novo Nordisk Inc | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OMNITROPE omnitrope |
2025 | Omnitrope | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sandoz Inc. Exact reporting entity; no affiliate inference |
2025 | OMNITROPE open payments reported associated product |
CMS Open Payments — General Payments 65 supporting records · 52 recipient NPIs · example record 1181967227 |
Omnitrope · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Liothyronine Sodium | Liothyronine Sodium | 432 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 103 |
| Synthroid | Levothyroxine Sodium | 219 | 52 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 217 | 70 |
| Jardiance | Empagliflozin | 180 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 155 | 50 |
| Calcitriol | Calcitriol | 131 | 36 |
| Paricalcitol | Paricalcitol | 113 | 39 |
| Mounjaro | Tirzepatide | 111 | 22 |
| Clonidine Hcl | Clonidine Hcl | 103 | 28 |
| Aliskiren | Aliskiren Hemifumarate | 99 | 23 |
| Memantine Hcl | Memantine Hcl | 99 | 26 |
| Metformin Hcl | Metformin Hcl | 95 | 25 |
| Genotropin | Somatropin | 90 | 12 |
| Indapamide | Indapamide | 90 | 34 |
| Lorazepam | Lorazepam | 80 | 14 |
| Estradiol | Estradiol | 78 | 21 |
| Repatha Sureclick | Evolocumab | 77 | 18 |
| Ezetimibe | Ezetimibe | 73 | 19 |
| Alprazolam | Alprazolam | 58 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 56 | 17 |
| Diclofenac Potassium | Diclofenac Potassium | 56 | 13 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Praluent Pen | Alirocumab | 53 | suppressed |
| Irbesartan | Irbesartan | 47 | suppressed |
| Rayaldee | Calcifediol | 47 | suppressed |
| Progesterone | Progesterone, Micronized | 46 | 14 |
| Potassium Chloride | Potassium Chloride | 43 | 16 |
| Spironolactone | Spironolactone | 42 | 17 |
| Gabapentin | Gabapentin | 41 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 36 | 13 |
| Estradiol (Twice Weekly) | Estradiol | 36 | 12 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 35 | 11 |
| Diazepam | Diazepam | 35 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 35 | 11 |
| Omeprazole | Omeprazole | 35 | suppressed |
| Dexamethasone | Dexamethasone | 33 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 32 | 11 |
| Hydrocortisone | Hydrocortisone | 32 | 11 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Doxercalciferol | Doxercalciferol | 29 | 11 |
| Omnitrope | Somatropin | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Armodafinil | Armodafinil | 26 | suppressed |
| Teriparatide | Teriparatide | 26 | suppressed |
| Acetazolamide | Acetazolamide | 23 | suppressed |
| Cycloset | Bromocriptine Mesylate | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Corlanor | Ivabradine Hcl | 22 | suppressed |
| Dotti | Estradiol | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 20 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Norditropin Flexpro | Somatropin | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Cabergoline | Cabergoline | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Inpefa | Sotagliflozin | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Strensiq | Asfotase Alfa | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,627.41 · 42 records | Ascendis Pharma Endocrinology Inc | CRYSVITA, EVENITY, INCEPTIV, KEVEYIS, Kerendia, Korlym, LEQVIO, OMNITROPE, REPATHA, REZDIFFRA, Sogroya, TEPEZZA, TRYNGOLZA, TZIELD, VYKAT XR, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error